Cargando…

Chinmedomics Strategy for Elucidating the Pharmacological Effects and Discovering Bioactive Compounds From Keluoxin Against Diabetic Retinopathy

Keluoxin (KLX) is an active agent in the treatment of diabetic retinopathy (DR). However, its mechanism, targets, and effective constituents against DR are still unclear, which seriously restricts its clinical application. Chinmedomics has the promise of explaining the pharmacological effects of her...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Ling, Sun, Ye, Sun, Hui, Zhang, Ai-hua, Zhang, Bo, Ge, Nan, Wang, Xi-jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008273/
https://www.ncbi.nlm.nih.gov/pubmed/35431942
http://dx.doi.org/10.3389/fphar.2022.728256
_version_ 1784687014523699200
author Kong, Ling
Sun, Ye
Sun, Hui
Zhang, Ai-hua
Zhang, Bo
Ge, Nan
Wang, Xi-jun
author_facet Kong, Ling
Sun, Ye
Sun, Hui
Zhang, Ai-hua
Zhang, Bo
Ge, Nan
Wang, Xi-jun
author_sort Kong, Ling
collection PubMed
description Keluoxin (KLX) is an active agent in the treatment of diabetic retinopathy (DR). However, its mechanism, targets, and effective constituents against DR are still unclear, which seriously restricts its clinical application. Chinmedomics has the promise of explaining the pharmacological effects of herbal medicines and investigating the effective mechanisms. The research results from electroretinography and electron microscope showed that KLX could reduce retinal dysfunction and pathological changes by the DR mouse model. Based on effectiveness, we discovered 64 blood biomarkers of DR by nontargeted metabolomics analysis, 51 of which returned to average levels after KLX treatment including leukotriene D4 and A4, l-tryptophan, 6-hydroxymelatonin, l-phenylalanine, l-tyrosine, and gamma-linolenic acid (GLA). The metabolic pathways involved were phenylalanine metabolism, steroid hormone biosynthesis, sphingolipid metabolism, etc. Adenosine monophosphate-activated protein kinase (AMPK), extracellular signal-regulated protein kinase1/2 (ERK1/2), phosphatidylinositol-3-kinase (PI3K), and protein 70 S6 kinase (p70 S6K) might be potential targets of KLX against DR. This was related to the mammalian target of rapamycin (mTOR) signaling and AMPK signaling pathways. We applied the chinmedomics strategy, integrating serum pharm-chemistry of traditional Chinese medicine (TCM) with metabolomics, to discover astragaloside IV (AS-IV), emodin, rhein, chrysophanol, and other compounds, which were the core effective constituents of KLX when against DR. Our study was the first to apply the chinmedomics strategy to discover the effective constituents of KLX in the treatment of DR, which fills the gap of unclear effective constituents of KLX. In the next step, the research of effective constituents can be used to optimize prescription preparation, improve the quality standard, and develop an innovative drug.
format Online
Article
Text
id pubmed-9008273
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90082732022-04-15 Chinmedomics Strategy for Elucidating the Pharmacological Effects and Discovering Bioactive Compounds From Keluoxin Against Diabetic Retinopathy Kong, Ling Sun, Ye Sun, Hui Zhang, Ai-hua Zhang, Bo Ge, Nan Wang, Xi-jun Front Pharmacol Pharmacology Keluoxin (KLX) is an active agent in the treatment of diabetic retinopathy (DR). However, its mechanism, targets, and effective constituents against DR are still unclear, which seriously restricts its clinical application. Chinmedomics has the promise of explaining the pharmacological effects of herbal medicines and investigating the effective mechanisms. The research results from electroretinography and electron microscope showed that KLX could reduce retinal dysfunction and pathological changes by the DR mouse model. Based on effectiveness, we discovered 64 blood biomarkers of DR by nontargeted metabolomics analysis, 51 of which returned to average levels after KLX treatment including leukotriene D4 and A4, l-tryptophan, 6-hydroxymelatonin, l-phenylalanine, l-tyrosine, and gamma-linolenic acid (GLA). The metabolic pathways involved were phenylalanine metabolism, steroid hormone biosynthesis, sphingolipid metabolism, etc. Adenosine monophosphate-activated protein kinase (AMPK), extracellular signal-regulated protein kinase1/2 (ERK1/2), phosphatidylinositol-3-kinase (PI3K), and protein 70 S6 kinase (p70 S6K) might be potential targets of KLX against DR. This was related to the mammalian target of rapamycin (mTOR) signaling and AMPK signaling pathways. We applied the chinmedomics strategy, integrating serum pharm-chemistry of traditional Chinese medicine (TCM) with metabolomics, to discover astragaloside IV (AS-IV), emodin, rhein, chrysophanol, and other compounds, which were the core effective constituents of KLX when against DR. Our study was the first to apply the chinmedomics strategy to discover the effective constituents of KLX in the treatment of DR, which fills the gap of unclear effective constituents of KLX. In the next step, the research of effective constituents can be used to optimize prescription preparation, improve the quality standard, and develop an innovative drug. Frontiers Media S.A. 2022-03-31 /pmc/articles/PMC9008273/ /pubmed/35431942 http://dx.doi.org/10.3389/fphar.2022.728256 Text en Copyright © 2022 Kong, Sun, Sun, Zhang, Zhang, Ge and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Kong, Ling
Sun, Ye
Sun, Hui
Zhang, Ai-hua
Zhang, Bo
Ge, Nan
Wang, Xi-jun
Chinmedomics Strategy for Elucidating the Pharmacological Effects and Discovering Bioactive Compounds From Keluoxin Against Diabetic Retinopathy
title Chinmedomics Strategy for Elucidating the Pharmacological Effects and Discovering Bioactive Compounds From Keluoxin Against Diabetic Retinopathy
title_full Chinmedomics Strategy for Elucidating the Pharmacological Effects and Discovering Bioactive Compounds From Keluoxin Against Diabetic Retinopathy
title_fullStr Chinmedomics Strategy for Elucidating the Pharmacological Effects and Discovering Bioactive Compounds From Keluoxin Against Diabetic Retinopathy
title_full_unstemmed Chinmedomics Strategy for Elucidating the Pharmacological Effects and Discovering Bioactive Compounds From Keluoxin Against Diabetic Retinopathy
title_short Chinmedomics Strategy for Elucidating the Pharmacological Effects and Discovering Bioactive Compounds From Keluoxin Against Diabetic Retinopathy
title_sort chinmedomics strategy for elucidating the pharmacological effects and discovering bioactive compounds from keluoxin against diabetic retinopathy
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008273/
https://www.ncbi.nlm.nih.gov/pubmed/35431942
http://dx.doi.org/10.3389/fphar.2022.728256
work_keys_str_mv AT kongling chinmedomicsstrategyforelucidatingthepharmacologicaleffectsanddiscoveringbioactivecompoundsfromkeluoxinagainstdiabeticretinopathy
AT sunye chinmedomicsstrategyforelucidatingthepharmacologicaleffectsanddiscoveringbioactivecompoundsfromkeluoxinagainstdiabeticretinopathy
AT sunhui chinmedomicsstrategyforelucidatingthepharmacologicaleffectsanddiscoveringbioactivecompoundsfromkeluoxinagainstdiabeticretinopathy
AT zhangaihua chinmedomicsstrategyforelucidatingthepharmacologicaleffectsanddiscoveringbioactivecompoundsfromkeluoxinagainstdiabeticretinopathy
AT zhangbo chinmedomicsstrategyforelucidatingthepharmacologicaleffectsanddiscoveringbioactivecompoundsfromkeluoxinagainstdiabeticretinopathy
AT genan chinmedomicsstrategyforelucidatingthepharmacologicaleffectsanddiscoveringbioactivecompoundsfromkeluoxinagainstdiabeticretinopathy
AT wangxijun chinmedomicsstrategyforelucidatingthepharmacologicaleffectsanddiscoveringbioactivecompoundsfromkeluoxinagainstdiabeticretinopathy